StreetAlpha.app
Home › Stocks › DMRA

Damora Therapeutics, Inc. (DMRA)

Healthcare
$22.56
▲ +0.29%
LAST CLOSE · NOV 17

Damora Therapeutics is a Waltham biopharmaceutical company developing antibody treatments for blood disorders. It last closed at $22.56 on Nov 17, up 0.29% on the day.

AI Auto Pilots
Is DMRA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$291.7M
Valuation
Market cap
$1.4B
61.9M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$349.7M
At Sep 30
Shareholder equity
$495.8M
Shares outstanding
61.9M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$51.8M−$51.8MFY2021FY2022: −$61.6M−$61.6MFY2022FY2023: −$38.3M−$38.3MFY2023FY2024: −$21.4M−$21.4MFY2024FY2025: −$209.8M−$209.8MFY2025

From DMRA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated DMRA in the past 90 days, not enough for a consensus
Average 12-month target
$59.00
▲ 161.5% upside

Based on 1 analyst who set a price target on DMRA in the past 90 days. The average target is $59.00, with a high of $59.00 and a low of $59.00, compared with the last close of $22.56.

Low $59.00Avg $59.00High $59.00
Blue marker: last close $22.56
Highest target$59.00
Average target$59.00
Lowest target$59.00
Latest rating changes
GuggenheimMaintained
Nov 6Buy$59
GuggenheimMaintained
Sep 25Buy$60
WedbushTarget raised
Jul 30Buy$35 → $40
JefferiesInitiated
Jul 27Buy$50
WedbushReiterated
Jun 12Buy$35
DateFirmActionRatingPrice target
Nov 6GuggenheimMaintainedBuy$59
Sep 25GuggenheimMaintainedBuy$60
Jul 30WedbushTarget raisedBuy$35 → $40
Jul 27JefferiesInitiatedBuy$50
Jun 12WedbushReiteratedBuy$35
Loading…

Technical Analysis

DMRA · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock is 1% above its 20 day and 3% above its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the Pivot at $22.40, and the nearest resistance the swing high (Oct 21) at $22.68.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 7.5%/day
Key levels
$38.3352 week high+69.9%
$25.81100 day average+14.4%
$25.45200 day average+12.8%
$22.91Pivot R1+1.6%
$22.68Swing high (Oct 21)+0.5%
$22.56Last close
$22.40Pivot−0.7%
$22.2520 day average−1.4%
$22.05Pivot S1−2.3%
$21.9150 day average−2.9%
$20.75Swing low (Nov 5)−8.0%
$15.7652 week low−30.1%
Indicators
RSI (14)52.06Middle of its rangeNeutral
MACD0.25Above its signal lineBullish
Stochastic38.1Middle of its rangeNeutral
ADX (14)19.1No clear trend
Williams %R-58.1Oversold below −80, overbought above −20Neutral
CCI (20)13.5Oversold below −100, overbought above 100Neutral
Rate of change+2.2%Change over 10 sessionsBullish
ATR (14)$1.69Typical daily range, 7.5% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for DMRA

What happened before

See how DMRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow DMRA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DMRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in DMRA in the last 90 days.

Loading…

See today’s whale options flow across the market →

DMRA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 2 selling
  • ▲Held by funds +95.8 pts
  • ▲Funds holding +108
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1113+3600.0%
In funds' top 1040–
Held by funds95.9%0.1%+95.8 pts
New / increased107 / 03 / 0+3466.7%
Reduced / sold out2 / 00 / 0–
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DMRA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DMRA is in one of them and how their past DMRA trades turned out.

DMRA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DMRA in an article yet. Here's the latest on the wider market.

About Damora Therapeutics

Damora Therapeutics is a biopharmaceutical company based in Waltham, Massachusetts, that develops treatments for blood disorders. Its lead candidate, DMR-001, is an antibody designed to target mutant calreticulin, a protein that drives essential thrombocythemia and myelofibrosis, two myeloproliferative neoplasms that affect the bone marrow. The company is also developing two related candidates for the same group of disorders. Its intended patients are people living with these conditions, and none of its candidates are on the market yet.

Headquarters
Waltham, MA